DelveInsight's 'Familial Hypercholesterolemia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Study Period: 2017-2030
The DelveInsight Familial Hypercholesterolemia epidemiology report gives a thorough understanding of the Familial Hypercholesterolemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Familial Hypercholesterolemia in the US, Europe, and Japan. The report covers the detailed information of the Familial Hypercholesterolemia epidemiology scenario in seven major countries (US, EU5, and Japan).
The Familial Hypercholesterolemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Familial Hypercholesterolemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Familial Hypercholesterolemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
The Familial Hypercholesterolemia epidemiology covered in the report provides historical as well as forecasted Familial Hypercholesterolemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Familial Hypercholesterolemia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
1. Key Insights
2. Executive Summary of Familial Hypercholesterolemia
3. Familial Hypercholesterolemia: Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Familial Hypercholesterolemia Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Familial Hypercholesterolemia Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Familial Hypercholesterolemia Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Familial Hypercholesterolemia Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Familial Hypercholesterolemia Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Familial Hypercholesterolemia Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Familial Hypercholesterolemia Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Familial Hypercholesterolemia Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Familial Hypercholesterolemia Treatment and Management
6.2. Familial Hypercholesterolemia Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
Table 1 Familial Hypercholesterolemia Epidemiology in 7MM (2017-2030)
Table 2 Familial Hypercholesterolemia Diagnosed and Treatable Cases in 7MM (2017-2030)
Table 3 Familial Hypercholesterolemia Epidemiology in the United States (2017-2030)
Table 4 Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 Familial Hypercholesterolemia Epidemiology in Germany (2017-2030)
Table 6 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 Familial Hypercholesterolemia Epidemiology in France (2017-2030)
Table 8 Familial Hypercholesterolemia Diagnosed and Treatable Cases in France (2017-2030)
Table 9 Familial Hypercholesterolemia Epidemiology in Italy (2017-2030)
Table 10 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 Familial Hypercholesterolemia Epidemiology in Spain (2017-2030)
Table 12 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 Familial Hypercholesterolemia Epidemiology in the United Kingdom (2017-2030)
Table 14 Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Table 15 Familial Hypercholesterolemia Epidemiology in Japan (2017-2030)
Table 16 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 1 Familial Hypercholesterolemia Epidemiology in 7MM (2017-2030)
Figure 2 Familial Hypercholesterolemia Diagnosed and Treatable Cases in 7MM (2017-2030)
Figure 3 Familial Hypercholesterolemia Epidemiology in the United States (2017-2030)
Figure 4 Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 Familial Hypercholesterolemia Epidemiology in Germany (2017-2030)
Figure 6 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 Familial Hypercholesterolemia Epidemiology in France (2017-2030)
Figure 8 Familial Hypercholesterolemia Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 Familial Hypercholesterolemia Epidemiology in Italy (2017-2030)
Figure 10 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 Familial Hypercholesterolemia Epidemiology in Spain (2017-2030)
Figure 12 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 Familial Hypercholesterolemia Epidemiology in the United Kingdom (2017-2030)
Figure 14 Familial Hypercholesterolemia Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
Figure 15 Familial Hypercholesterolemia Epidemiology in Japan (2017-2030)
Figure 16 Familial Hypercholesterolemia Diagnosed and Treatable Cases in Japan (2017-2030)
*The table of contents is not exhaustive; will be provided in the final report
